SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HuMAB companies
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: nigel bates1/23/2015 4:41:40 AM
   of 1022
 
GHENT, Belgium, 22 January 2015 – Ablynx [Euronext Brussels: ABLX] today announced that it has been successful in opposing the appeal lodged by Domantis (now a member of the GlaxoSmithKline, GSK, group of companies) in 2010 against the decision by the Opposition Division of the European Patent Office to revoke Domantis’ European Patent 1 517 921. As a result of the decision by the Board of Appeal, the Domantis patent will remain revoked in full (without further possibility to appeal).
The European Patent 1 517 921 relates to one specific technique for the half-life extension of immunoglobulin single variable domains. Now that the revocation of this patent has been confirmed in appeal, Ablynx and its partners remain free to apply such half-life extension techniques in their internal and partnered programmes, as Domantis has no granted patent claims that could possibly be invoked against the use of these techniques in Europe.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News